Search Results - "Targeted oncology"

An Overview of PARP Inhibitors for the Treatment of Breast Cancer by Cortesi, Laura, Rugo, Hope S., Jackisch, Christian

“…Loss-of-function mutations in BRCA1 and BRCA2 are detected in at least 5% of unselected patients with breast cancer (BC). These BC susceptibility genes encode…”
Get full text

MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside by Ratti, Margherita, Lampis, Andrea, Ghidini, Michele, Salati, Massimiliano, Mirchev, Milko B., Valeri, Nicola, Hahne, Jens C.

“…Non-coding RNAs represent a significant proportion of the human genome. After having been considered as ‘junk’ for a long time, non-coding RNAs are now well…”
Get full text

Vaccine Therapies for Cancer: Then and Now by Morse, Michael A., Gwin, William R., Mitchell, Duane A.

“…There are strong biologic and preclinical rationales for the development of therapeutic cancer vaccines; however, the clinical translation of this treatment…”
Get full text

Sorafenib: A Review in Hepatocellular Carcinoma by Keating, Gillian M.

“…Sorafenib (Nexavar ® ) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the results of the…”
Get full text

Impact of the COVID-19 Outbreak on the Management of Patients with Cancer by Raymond, Eric, Thieblemont, Catherine, Alran, Severine, Faivre, Sandrine

“…The coronavirus SARS-CoV-2 (COVID-19) outbreak is having a profound impact on the management of patients with cancer. In this review, we comprehensively…”
Get full text

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance by Raschi, Emanuel, Gatti, Milo, Gelsomino, Francesco, Ardizzoni, Andrea, Poluzzi, Elisabetta, De Ponti, Fabrizio

“…The advent of immune checkpoint inhibitors (ICIs) caused a paradigm shift both in drug development and clinical practice; however, by virtue of their mechanism…”
Get full text

PARP Inhibition in Cancer: An Update on Clinical Development by Sachdev, Esha, Tabatabai, Roya, Roy, Varun, Rimel, B. J., Mita, Monica M.

“…PARP (poly(ADP-ribose) polymerase) inhibitors represent a novel class of anti-cancer therapy; they take advantage of synthetic lethality and induce cell death…”
Get full text

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study by Cheng, Ying, He, Yong, Li, Wei, Zhang, He-long, Zhou, Qing, Wang, Buhai, Liu, Chunling, Walding, Andrew, Saggese, Matilde, Huang, Xiangning, Fan, Minhao, Wang, Jia, Ramalingam, Suresh S.

“…Background In the global FLAURA study, first-line osimertinib, a third-generation irreversible tyrosine kinase inhibitor (TKI) of epidermal growth factor…”
Get full text

Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma by Mollica, Veronica, Santoni, Matteo, Matrana, Marc R., Basso, Umberto, De Giorgi, Ugo, Rizzo, Alessandro, Maruzzo, Marco, Marchetti, Andrea, Rosellini, Matteo, Bleve, Sara, Maslov, Diana, Tawagi, Karine, Philon, Ernest, Blake, Zoe, Massari, Francesco

“…Background Immune checkpoint inhibitors (ICIs) represent the standard of care as first- or second-line treatment in patients with renal cell carcinoma (RCC)…”
Get full text

PARP Inhibitors in Ovarian Cancer: A Review by O’Malley, David M., Krivak, Thomas C., Kabil, Nashwa, Munley, Jiefen, Moore, Kathleen N.

“…Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have transformed the ovarian cancer (OC) treatment landscape. This narrative review provides a…”
Get full text

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer by Bauer, Todd M., Shaw, Alice T., Johnson, Melissa L., Navarro, Alejandro, Gainor, Justin F., Thurm, Holger, Pithavala, Yazdi K., Abbattista, Antonello, Peltz, Gerson, Felip, Enriqueta

“…Background Lorlatinib is a potent, third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) designed to penetrate the blood–brain barrier. Objective We report…”
Get full text

Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies by Simpson, Aaron, Petnga, Wilfride, Macaulay, Valentine M., Weyer-Czernilofsky, Ulrike, Bogenrieder, Thomas

“…Despite a strong preclinical rationale for targeting the insulin-like growth factor (IGF) axis in cancer, clinical studies of IGF-1 receptor (IGF-1R)-targeted…”
Get full text

Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations by Makvandi, Mehran, Dupis, Edouard, Engle, Jonathan W., Nortier, F. Meiring, Fassbender, Michael E., Simon, Sam, Birnbaum, Eva R., Atcher, Robert W., John, Kevin D., Rixe, Olivier, Norenberg, Jeffrey P.

“…Alpha-emitters are radionuclides that decay through the emission of high linear energy transfer α-particles and possess favorable pharmacologic profiles for…”
Get full text

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib by Hochmair, Maximilian J., Buder, Anna, Schwab, Sophia, Burghuber, Otto C., Prosch, Helmut, Hilbe, Wolfgang, Cseh, Agnieszka, Fritz, Richard, Filipits, Martin

“…Background Acquired epidermal growth factor receptor (EGFR) T790M mutation is the primary resistance mechanism to first-generation EGFR tyrosine kinase…”
Get full text

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars by Rosen, Lee S., Jacobs, Ira A., Burkes, Ronald L.

“…Colorectal cancer (CRC) is a leading cause of tumor-related morbidity and mortality worldwide, with mortality most often attributable to metastatic disease…”
Get full text

Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond by Cohen, Romain, Rousseau, Benoît, Vidal, Joana, Colle, Raphaël, Diaz, Luis A., André, Thierry

“…Immune checkpoints inhibitors (ICIs) have been a breakthrough, with unique response and survival patterns compared with chemotherapy for patients with advanced…”
Get full text

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial by Shore, Neal, Zurth, Christian, Fricke, Robert, Gieschen, Hille, Graudenz, Kristina, Koskinen, Mikko, Ploeger, Bart, Moss, Jonathan, Prien, Olaf, Borghesi, Gustavo, Petrenciuc, Oana, Tammela, Teuvo L., Kuss, Iris, Verholen, Frank, Smith, Matthew R., Fizazi, Karim

“…Background Darolutamide, an androgen receptor antagonist with a distinct molecular structure, significantly prolonged metastasis-free survival versus placebo…”
Get full text

Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis by Iacovelli, Roberto, Nolè, Franco, Verri, Elena, Renne, Giuseppe, Paglino, Chiara, Santoni, Matteo, Cossu Rocca, Maria, Giglione, Palma, Aurilio, Gaetano, Cullurà, Daniela, Cascinu, Stefano, Porta, Camillo

“…Background Several clinical trials have reported that therapies targeting programmed death-1 (PD1) and its ligand (PD-L1) improve patient outcomes, while tumor…”
Get full text

Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features by Shirley, Matt

“…Starting with the first-in-class agent ibrutinib, the development of Bruton tyrosine kinase (BTK) inhibitors has led to dramatic improvements in the management…”
Get full text

Targeting Toll-Like Receptors for Cancer Therapy by Braunstein, Marc J., Kucharczyk, John, Adams, Sylvia

“…The immune system encompasses a broad array of defense mechanisms against foreign threats, including invading pathogens and transformed neoplastic cells…”
Get full text